You searched for: daunorubicin (Engelska - Danska)

daunorubicin, doxorubicin, paclitaxel, or topotecan for cancer
daunorubicin, doxorubicin, paclitaxel eller topotecan mod kræft

daunorubicin 45 mg/ m2 i.v., days 6-7, 13-14
45 mg/m2 i.v., dag 6-7, 13-14

daunorubicin 30 mg/m2 i.v., days 1-3, 15-16; v
daunorubicin 30 mg/m² i.v., dag 1-3, 15-16;

daunorubicin, doxorubicin, imatinib, irinotecan, lapatinib, mitoxantrone, topotecan concentrations may increase.
koncentrationerne af daunorubicin, doxorubicin, imatinib, irinotecan, lapatinib, mitoxantron eller topotecan kan stige.

metformin, used for diabetes, daunorubicin, doxorubicin, imatinib, irinotecan, lapatinib, mitoxantrone, topotecan, used for different sorts of cancer.
metformin, der bruges til behandling af diabetes daunorubicin, doxorubicin, imatinib, irinotecan, lapatinib, mitoxantron, topotecan, der bruges til behandling af forskellige former for kræft

daunorubicin, doxorubicin, imatinib, irinotecan, lapatinib, mitoxantrone or topotecan: careful monitoring for any occurrence of drug toxicity, and dose reduction if required.
daunorubicin, doxorubicin, imatinib, irinotecan, lapatinib, mitoxantron eller topotecan: nøje monitorering for forekomst af eventuel lægemiddeltoksicitet og om nødvendigt reduktion af dosis.

emetogenic chemotherapies administered included doxorubicin, cyclophosphamide (<1500 mg/m2), ifosfamide, cisplatin, dactinomycin, carboplatin, and daunorubicin.
de administrerede emetogene kemoterapeutika omfattede doxorubicin, cyclophosphamid (<1.500 mg/m2), ifosfamid, cisplatin, dactinomycin, carboplatin og daunorubicin.

(1 h) , days 1-5; vm26 60 mg/m2 i. v.(1 h) , days 1-5 consolidation therapy ii, iv study aau02 daunorubicin 30 mg/m2 i. v., days 1-3, 15-16; vcr 2 mg total dose i. v., induction therapy (de days 1, 8, 15, 22; cp 750 mg/m2 i. v., days 1, 8; prednisone 60 mg/m2 novo ph+ all) oral, days 1-7, 15-21; ida 9 mg/m2 oral, days 1-28; mtx 15 mg intrathecal, days 1, 8, 15, 22; ara-c 40 mg intrathecal, days 1, 8, 15, 22; methylprednisolone 40 mg intrathecal, days 1, 8, 15, 22 ara-c 1,000 mg/m2/12 h i. v. (3 h) , days 1-4; mitoxantrone 10 mg/m2 i. v.consolidation (denovo ph+ all) study ade04 prephase
behandling i, iii, v konsoliderende behandling ii, iv studie aau02 induktionsbehandling (de novo ph+ all)konsoliderende behandling (de novo ph+ all) studie ade04 præfaseinduktionsbehandling i induktionsbehandling ii konsoliderende behandling studie ajp01 induktionsbehandling